• Je něco špatně v tomto záznamu ?

Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response

V. Hlaváč, R. Václavíková, V. Brynychová, P. Ostašov, R. Koževnikovová, K. Kopečková, D. Vrána, J. Gatěk, P. Souček

. 2021 ; 22 (6) : . [pub] 20210310

Jazyk angličtina Země Švýcarsko

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019068

Grantová podpora
NV19-08-00113 Czech Medical Council
INTER-EXCELLENCE LTA-USA no. 19032 Czech Ministry of Education, Youth and Sports
Progress Q39 Charles University Research Fund

Breast cancer is the most frequent cancer in the female population worldwide. The role of germline genetic variability in cytochromes P450 (CYP) in breast cancer prognosis and individualized therapy awaits detailed elucidation. In the present study, we used the next-generation sequencing to assess associations of germline variants in the coding and regulatory sequences of all human CYP genes with response of the patients to the neoadjuvant cytotoxic chemotherapy and disease-free survival (n = 105). A total of 22 prioritized variants associating with a response or survival in the above evaluation phase were then analyzed by allelic discrimination in the large confirmation set (n = 802). Associations of variants in CYP1B1, CYP4F12, CYP4X1, and TBXAS1 with the response to the neoadjuvant cytotoxic chemotherapy were replicated by the confirmation phase. However, just association of variant rs17102977 in CYP4X1 passed the correction for multiple testing and can be considered clinically and statistically validated. Replicated associations for variants in CYP4X1, CYP24A1, and CYP26B1 with disease-free survival of all patients or patients stratified to subgroups according to therapy type have not passed a false discovery rate test. Although statistically not confirmed by the present study, the role of CYP genes in breast cancer prognosis should not be ruled out. In conclusion, the present study brings replicated association of variant rs17102977 in CYP4X1 with the response of patients to the neoadjuvant cytotoxic chemotherapy and warrants further research of genetic variation CYPs in breast cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019068
003      
CZ-PrNML
005      
20240125102923.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22062826 $2 doi
035    __
$a (PubMed)33802237
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hlaváč, Viktor $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic
245    10
$a Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response / $c V. Hlaváč, R. Václavíková, V. Brynychová, P. Ostašov, R. Koževnikovová, K. Kopečková, D. Vrána, J. Gatěk, P. Souček
520    9_
$a Breast cancer is the most frequent cancer in the female population worldwide. The role of germline genetic variability in cytochromes P450 (CYP) in breast cancer prognosis and individualized therapy awaits detailed elucidation. In the present study, we used the next-generation sequencing to assess associations of germline variants in the coding and regulatory sequences of all human CYP genes with response of the patients to the neoadjuvant cytotoxic chemotherapy and disease-free survival (n = 105). A total of 22 prioritized variants associating with a response or survival in the above evaluation phase were then analyzed by allelic discrimination in the large confirmation set (n = 802). Associations of variants in CYP1B1, CYP4F12, CYP4X1, and TBXAS1 with the response to the neoadjuvant cytotoxic chemotherapy were replicated by the confirmation phase. However, just association of variant rs17102977 in CYP4X1 passed the correction for multiple testing and can be considered clinically and statistically validated. Replicated associations for variants in CYP4X1, CYP24A1, and CYP26B1 with disease-free survival of all patients or patients stratified to subgroups according to therapy type have not passed a false discovery rate test. Although statistically not confirmed by the present study, the role of CYP genes in breast cancer prognosis should not be ruled out. In conclusion, the present study brings replicated association of variant rs17102977 in CYP4X1 with the response of patients to the neoadjuvant cytotoxic chemotherapy and warrants further research of genetic variation CYPs in breast cancer.
650    12
$a nádory prsu $x farmakoterapie $x enzymologie $x genetika $x mortalita $7 D001943
650    12
$a systém (enzymů) cytochromů P-450 $x genetika $x metabolismus $7 D003577
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genetická variace $7 D014644
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a neoadjuvantní terapie $7 D020360
650    12
$a nádorové proteiny $x genetika $x metabolismus $7 D009363
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Václavíková, Radka $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Brynychová, Veronika $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Ostašov, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Koževnikovová, Renata $u Department of Oncosurgery, MEDICON, 140 00 Prague, Czech Republic $7 xx0313059
700    1_
$a Kopečková, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 00 Prague, Czech Republic
700    1_
$a Vrána, David $u Comprehensive Cancer Center Novy Jicin, Hospital Novy Jicin, 741 01 Novy Jicin, Czech Republic
700    1_
$a Gatěk, Jiří $u Department of Surgery, EUC Hospital Zlin and Tomas Bata University in Zlin, 763 02 Zlin, Czech Republic
700    1_
$a Souček, Pavel $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33802237 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20240125102918 $b ABA008
999    __
$a ok $b bmc $g 1689991 $s 1139514
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 6 $e 20210310 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NV19-08-00113 $p Czech Medical Council
GRA    __
$a INTER-EXCELLENCE LTA-USA no. 19032 $p Czech Ministry of Education, Youth and Sports
GRA    __
$a Progress Q39 $p Charles University Research Fund
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace